Skip to main content
Atrás
KRYS logo

Krystal Biotech, Inc.

Calidad de datos: 100%
KRYS
NASDAQ Healthcare Biotechnology
$245.39
▼ $6.01 (-2.39%)
Cap. Mercado: 7.17B
Rango del Día
$242.26 $249.60
Rango de 52 Semanas
$122.80 $298.30
Volumen
282,422
Promedio 50D / 200D
$269.80 / $199.95
Cierre Anterior
$251.40

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (633 pares)

Métrica Acción Mediana del Sector
P/E 35.0 0.2
P/B 5.9 2.8
ROE % 18.9 3.7
Net Margin % 52.6 3.9
Rev Growth 5Y % — 9.7
D/E 0.0 0.2

Precio Objetivo de Analistas

Hold
$311.00 +26.7%
Low: $224.00 High: $371.00
P/E Futuro
33.10
EPS Futuro
$7.70
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
527.13M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $27.11
$20.97 – $34.60
 1.45B 1
FY2029 $20.30
$15.70 – $25.90
 1.15B 1
FY2028 $13.46
$8.34 – $27.13
 899.45M 5

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-17 $1.54 $1.70 +10.4%
2025-11-03 $1.12 $2.66 +137.5%
2025-08-04 $1.08 $1.29 +19.4%
2025-05-06 $1.38 $1.20 -13.0%
2025-02-19 $1.29 $1.52 +17.8%
2024-11-04 $0.90 $0.91 +1.1%
2024-08-05 $0.50 $0.86 +72.0%
2024-05-06 $0.15 $0.03 -80.0%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Earnings grew 129.74% over the past year
ROE of 18.91% — decent returns on equity
Net margin of 52.64% shows strong profitability
Debt/Equity of 0.01 — conservative balance sheet
Generating 188.91M in free cash flow
P/E of 35.02 — premium valuation

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)33.94%
Earnings (1Y)129.74%
FCF Growth (3Y)N/A

Calidad

Return on Equity
18.91%
ROIC9.84%
Net Margin52.64%
Op. Margin41.45%

Seguridad

Debt / Equity
0.01
Current Ratio9.95
Interest Coverage0.00

Valoración

P/E Ratio
35.02
Forward P/E33.10
P/B Ratio5.88
EV/EBITDA41.45
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 33.94% Revenue Growth (3Y) 177.04%
Earnings Growth (1Y) 129.74% Earnings Growth (3Y) 332.86%
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 389.13M Net Income (TTM) 204.83M
ROE 18.91% ROA 15.36%
Gross Margin 92.61% Operating Margin 41.45%
Net Margin 52.64% Free Cash Flow (TTM) 188.91M
ROIC 9.84% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 9.95
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 35.02 Forward P/E 33.10
P/B Ratio 5.88 P/S Ratio 18.43
PEG Ratio 0.27 Forward PEG N/A
EV/EBITDA 41.45 Fwd EV/EBITDA 35.05
Forward P/S 13.61 Fwd Earnings Yield 3.02%
FCF Yield 2.63%
Market Cap 7.17B Enterprise Value 6.69B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 389.13M 290.52M 50.70M 0.0 0.0
Net Income 204.83M 89.16M 10.93M -139.98M -69.57M
EPS (Diluted) 6.84 3.00 0.39 -5.49 -3.13
Gross Profit 360.36M 270.45M 47.61M 0.0 0.0
Operating Income 161.30M 65.70M -109.73M -145.20M -68.28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.33B 1.06B 818.36M 558.45M 626.30M
Total Liabilities 114.23M 109.46M 39.71M 36.22M 32.72M
Shareholders' Equity 1.22B 946.38M 778.64M 522.23M 593.58M
Total Debt 9.34M 7.26M 8.09M 8.93M 8.02M
Cash & Equivalents 496.30M 344.87M 358.33M 161.90M 341.25M
Current Assets 1.02B 742.05M 587.91M 383.78M 442.27M
Current Liabilities 102.94M 102.00M 33.09M 28.85M 25.74M